Association between interleukin 28B polymorphism and sustained virological response to sofosbuvir plus daclatasvir in chronic hepatitis C genotype 4 Egyptian patients
- 25 March 2021
- journal article
- research article
- Published by Wiley in Journal of Clinical Pharmacy and Therapeutics
- Vol. 46 (4) , 942-949
Abstract
What is known and objective Sofosbuvir has been approved as the first nonstructural protein 5B polymerase inhibitor with pan‐genotypic activity against the hepatitis C (HCV) virus. Daclatasvir is a first‐in‐class hepatitis C virus nonstructural protein 5A replication complex inhibitor. We aimed to evaluate the usefulness of the reference single nucleotide polymorphism (rs12979860) interleukin 28B (CC genotype) for predicting sustained virological response to sofosbuvir plus daclatasvir in Egyptian patients infected with HCV‐4. Methods Samples were collected at week zero. One hundred and thirty‐one patients who reached the end of treatment (at week 12) were divided into three groups, according to their interleukin 28B genotype: Group A included 31 patients (CC genotype), group B included 79 patients (CT genotype) and group C had 21 patients (TT genotype). All patients received treatment for 3 months in the form of sofosbuvir plus daclatasvir with ribavirin (in case of cirrhotic patients) or without ribavirin (in case of non‐cirrhotic patients). Results and discussion Sustained virological response rate was significantly higher in patients with IL28B (CC genotype) vs. (non‐CC genotype) (100 vs.88%) (p < 0.0001).These patients also showed lower rates of post‐treatment relapse and non‐response, compared with the CT and TT patients (0% vs. (7.59% and 28.5%, respectively) (p < 0.0001). Also, patients with CC genotype showed higher sustained virological response than non‐CC genotypes on both cirrhotic (100% vs. 68.75%) and non‐cirrhotic patients (100% vs. 91.66%) (p ≤ 0.0001). What is new and conclusion Our results suggest that IL28B genotype contributes to the prediction of response to sofosbuvir plus daclatasvir.Keywords
This publication has 31 references indexed in Scilit:
- The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patientsVirology, 2013
- Epidemiology and natural history of HCV infectionNature Reviews Gastroenterology & Hepatology, 2013
- Hepatitis C Virus in Arab World: A State of ConcernThe Scientific World Journal, 2012
- IL28B Genotype Is Associated With Differential Expression of Intrahepatic Interferon-Stimulated Genes in Patients With Chronic Hepatitis CHepatology, 2010
- Replicated Association Between an IL28B Gene Variant and a Sustained Response to Pegylated Interferon and RibavirinGastroenterology, 2010
- Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearanceNature, 2009
- Global epidemiology of hepatitis C virus infectionThe Lancet Infectious Diseases, 2005
- Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirinJournal of Hepatology, 2005
- Natural history of chronic hepatitis CHepatology, 2002
- Histological grading and staging of chronic hepatitisJournal of Hepatology, 1995